54 results about "Antigens present" patented technology

The invention discloses a preparation method and application of a dual-targeting carrier-free delivery system for enhancing anti-tumor immunity of NKT cells, Lys-alpha-GalCer is used as a raw material, and two molecules of LGC are connected through a disulfide bond to synthesize an amphiphilic LGC-SS-LGC micromolecule prodrug; the LGC-SS-LGC micromolecule prodrug is prepared into vesicles internally loaded with an NKT cell antigen presenting molecule CD1d and externally modified with polysarcosine through electrostatic adsorption through a film dispersion-probe ultrasonic method, finally a CD1d / LGC-SS-LGC / PSar dual-targeting carrier-free delivery system is formed, and the dual-targeting carrier-free delivery system can be used for liver cancer treatment after intravenous administration. In addition, the compound can be used for preparing a preparation for enhancing NKT cell Th1 type immune response. The dual-targeting carrier-free delivery system prepared by the invention can directly or indirectly enhance the anti-tumor immune effect of the NKT cells, and has a dual-synergistic effect.

The present invention relates to epitopes of leucine-rich immunoglobulin-like domain 1 (Lrig-1), an antigen present on the surface of regulatory T cells, and antibodies or antigen-binding fragments that specifically bind thereto.

The present invention relates to an epitope of leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is an antigen present on the surface of regulatory T cells, and an antibody or antigen-binding fragment specifically binding thereto.

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.

The invention discloses a preparation method of a silicon dioxide nano vaccine for mediating constant natural killer T (iNKT) cells and application of the silicon dioxide nano vaccine in the field of tumor immunotherapy. The iNKT cell is a special T cell subset which can be activated by a glycolipid antigen presented by CD1d, and can directly kill tumor cells and activate other immune cells. Clinically, the classical agonist alpha GC of the iNKT cell can lead to function depletion of the iNKT cell after multiple intravenous administration, and finally evolves into an inactive state. Although the CD1d / alpha GC protein complex relieves the iNKT cell anenergetic state to a certain extent, the CD1d / alpha GC protein complex is easily degraded and cleared in a complex physiological environment, and the treatment effect is weakened. The characteristics of large aperture and high specific surface area of dendritic mesoporous silica are utilized, CD1d / alpha GC is loaded into a pore channel of a mesoporous nano-material, and the design can protect protein drugs from being degraded in blood circulation, so that a nano-vaccine capable of effectively mediating iNKT cells and successfully relieving the inability of the iNKT cells is constructed; and the effectiveness of the compound in tumor treatment is verified. The patent is supported by the national natural science fund (82001958).

The present invention provides novel antigens of an allergy to fish, methods and kits for diagnosing an allergy to fish, pharmaceutical compositions comprising such an antigen, fishes, fish eggs or processed products of such fish or fish egg in which such an antigen is eliminated, fishes that deliver such fish eggs or are born from such fish egg, and a tester for determining the presence or absence of a fish antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an antigen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and raw materials or processed products in which an antigen comprising such a polypeptide is eliminated or reduced. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

Provided herein are genetically modified rodent models of disease, wherein the rodent expresses at least an antigen presenting portion of a classical human leukocyte antigen (HLA) molecule, and comprises, in its periphery, human T cells, e.g., engineered human T cells genetically modified to express at least a recombinant human T cell receptor (TCR) variable domain that binds an antigen presented in the context of the antigen presenting portion of the HLA. Also provided herein are methods of making and using the same, e.g., for identifying therapeutic candidates for treatment of a disorder associated with an HLA-peptide-TCR interaction.

Disclosed are an artificial lymph node (aLN) comprising an extracellular matrix (ECM) hydrogel conjugated with an antigen presenting complex (Signal 1), a co-stimulatory ligand (Signal 2), and T cell-stimulating cytokine (Signal 3) and methods of their use for stimulating one or more T cells and treating a disease, disorder, or condition selected from a cancer, an infectious disease, and an autoimmune disease.

A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided

Chimeric antigen receptor (CAR) linking molecules and protein entities and dimers comprising an extracellular domain of an antigen present on a cancer cell and a first immune cell effector domain are disclosed, as well as their use in co-treatment of cancer with CAR immune cells.

The invention relates to the field of immune cells. According to the preparation method and application of the novel immune cell, lentivirus containing DNA molecules subjected to gene modification is used for transfecting cells in peripheral blood of mammals, so that the cells can be passaged for multiple times, and the cells have the antigen presenting capacity and the capacity of activating and amplifying natural killer cells. After the cell is further genetically modified, better transmembrane transfer, antigen presentation and natural killer cell activation can be realized. After gene modification, the cell and different cytokines or small molecules jointly activate and amplify mononuclear cells to obtain a larger number of natural killer cells with higher purity, epigenetics are regulated and controlled to change the receptor and ligand expression quantity of the natural killer cells, and then the cytotoxicity of effector cells is improved. The invention can be used for preparing antigen presenting cells and CTL cells aiming at different antigens and an application method. The cells and the using method have wide application prospects in the aspects of prevention and treatment of tumors and infectious diseases.

The present invention relates to in vitro methods of producing mature dendritic cells, a dendritic cell maturation cocktail, a method of producing mature antigen presenting dendritic cells in vitro, methods of manufacturing vaccines containing mature dendritic cells, antigen-presenting mature dendritic cells produced according to the methods described, vaccines containing the mature antigen-presenting dendritic cells and methods of treatment and used of mature antigen-presenting cells of the invention.

The present invention provides a method for expanding anti-tumor T cells comprising the steps of: a) providing a phagocyzable particle having one or more tumor neoantigen constructs in intimate association therewith wherein the tumor neoantigen constructs comprise an amino acid sequence comprising at least one mutant amino acid known or suspected of being associated with cancer in a subject, or a mutated or non-mutated amino acid sequence known or suspected of expression in cancer cells of the subject; b) providing a living antigen presenting cell; c) contacting the particles with the antigen presenting cells in vitro under conditions that allow the antigen presenting cells to phagocytize the particles; d) providing a T cell sample comprising live T cells from the subject; e) contacting the T cell sample with the antigen presenting cells in in vitro contact with the particles under conditions allowing specific activation of the anti-tumor T cells in response to the antigen presented by the antigen presenting cells. The invention also provides tumor neoantigen constructs as defined in the specification.

The present invention relates to antibodies or antigen-binding fragments that specifically bind to an epitope of a Lrig-1 (leucine-rich and immunoglobulin-like domain 1) protein, said Lrig-1 protein being an antigen present on the surface of regulatory T cells. The antibody or antigen-binding fragment specifically binding to the epitope of the Lrig-1 protein according to the present invention specifically binds to the epitope of the present invention existing in regulatory T cells, thereby regulating the function of regulatory T cells, maintaining or enhancing the activity of effector T cells, and can be very effectively used in the prevention, amelioration or treatment of various diseases.

Disclosed are immune cell enhancers containing a first moiety that binds a cytokine receptor on the immune cell, and a second moiety that binds a co-stimulatory receptor on the immune cell. Also disclosed are adoptive cell therapeutic systems. The system includes a) a chimeric antigen receptor (CAR) immune cell comprising a CAR that comprises an extracellular domain that binds an antigen present on a cancer cell, a transmembrane domain, and an endodomain comprising a co-stimulatory region, but not a stimulatory region comprising a CD3 protein and b) a CAR-enhancer comprising a first moiety that binds an extracellular domain on the CAR immune cell and a second moiety that binds a cytokine receptor on the immune cell and uses thereof to treat cancer. Further disclosed are pharmaceutical compositions containing an effective amount of the ICE or the system and a pharmaceutically acceptable carrier. And methods of treating cancer therewith.

Disclosed herein are nanoparticle immunoadjuvant complexes and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating or preventing a disease or disorder associated with an antigen presented on n nanoparticle immunoadjuvant complex in a subject in need thereof, by administering the antigen presenting nanoparticle immunoadjuvant complex, or encoding nucleic acid molecules, to the subject.

1. The material of the article to which this design relates is synthetic resin. 2. The article to which this design relates is a set of teaching tools that can be used to learn about ABO blood types and RhD blood types. 3. Teaching tool A represents red blood cells, teaching tool B represents type A antigens, teaching tool C represents type B antigens, teaching tool D represents RhD antigens, teaching tool E represents anti-type A antibodies, teaching tool F represents anti-type B antibodies, and teaching tool G represents anti-RhD antibodies. 4. The article to which this design relates is designed to easily explain the phenomenon of red blood cells and the antigens present on their surfaces reacting with antibodies in serum. 5. Reference Figures 1 to 3 show the product in use. Reference Figure 1 shows that when type B red blood cells are reacted with a type A person, the anti-B antibodies in the type A serum and the type B red blood cells agglutinate. Reference Figure 2 shows that when type A red blood cells are reacted with a type B person, the anti-A antibodies in the type B serum and the type A red blood cells agglutinate. Reference Figure 3 shows the RhD phenomenon, where red blood cells with RhD antigens on their surface agglutinate with anti-RhD antibodies.

The invention discloses an application of sodium cromoglycate in preparation of a pharmaceutical composition for promoting immunotherapy of breast cancer, and belongs to the technical field of tumor therapy, and the breast cancer is breast cancer with immunotherapy failure or immunotherapy drug-resistant breast cancer. The invention provides an application of sensitizing an immunotherapy drug in treatment of breast cancer by inducing antigen presenting related functional molecules on antigen presenting mast cells to be up-regulated by using sodium cromoglycate, remarkably enhancing antigen presenting mast cell mediated T cell anti-tumor immunity and inhibiting tumor growth resistant to immunotherapy. The sensitization immunotherapy curative effect of a mouse experiment shows that the sodium cromoglycate combined immunotherapy inhibits the growth of mouse breast tumor resistant to immunotherapy, and the prospective II-stage clinical test proves that the immunotherapy combined sodium cromoglycate has the curative effect and safety on a patient suffering from the triple negative breast cancer resistant to immunotherapy, and the immunotherapy combined sodium cromoglycate can be used for treating the triple negative breast cancer resistant to immunotherapy. The preset main curative effect end point is reached, and the adverse reaction is controllable.

The present embodiments provide for an S. aureus (SA). Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces a B-cell and T-cell immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. The present SA-MAPS immunogenic composition herein generates an immune response in a subject, preferably an antibody response and a B-cell and / or T-cell response, and can comprise at least one B-cell SA antigen and at least one T-cell SA antigen, and can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one, or multiple SA antigens at the same time.

(1) The purpose of the present invention is to provide an anti-tumor agent having an improved immune checkpoint inhibitor effect. (2) The purpose of the present invention is also to provide a drug which can exert an effect even in the absence of an antigen. (1) An antitumor agent formed by combining an immune checkpoint inhibitor and a liposome composition containing an NKT cell ligand. And (2) a liposome composition containing an NKT cell ligand and an antigen.

The present invention provides a method for expanding anti-tumor T cells, comprising the following steps: a) providing phagocytic particles having one or more tumor neoantigen constructs tightly associated therewith, wherein the tumor neoantigen construct comprises an amino acid sequence containing at least one mutated amino acid known or suspected to be associated with a subject's cancer, or a mutated or non-mutated amino acid sequence known or suspected to be expressed in a subject's cancer cells; b) providing live antigen-presenting cells; c) contacting the particles with the antigen-presenting cells in vitro under conditions that allow the antigen-presenting cells to phagocytose the particles; d) providing a T cell sample containing live T cells from the subject; e) contacting the T cell sample with the antigen-presenting cells contacted with the particles in vitro under conditions that allow the anti-tumor T cells to be specifically activated in response to antigens presented by the antigen-presenting cells. The present invention also provides a tumor neoantigen construct as defined in the specification.

The invention discloses a space-time controllable activated vaccine adjuvant, a vaccine as well as preparation methods and applications of the space-time controllable activated vaccine adjuvant and the vaccine. The vaccine adjuvant disclosed by the invention is formed by co-assembling polypeptide, a light / sound sensitive agent and a congenital immune signal agonist. The space-time controllable activated vaccine adjuvant disclosed by the invention can further entrap multiple disease type antigens to prepare a vaccine, controls and activates an antigen presenting cell innate immune signal channel through exogenous near-infrared light / ultrasound, induces I-type interferon secretion and enhances the antigen presenting efficiency so as to activate strong antigen specific cellular immune and humoral immune response, and can be used for preparing the vaccine. Therefore, tumor growth and metastasis are effectively inhibited, and the compound is expected to be further applied to prevention of infectious diseases.

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an allergen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and food raw materials or edible processed products in which an antigen comprising such a polypeptide is eliminated or reduced, or the polypeptide is cleaved or removed. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

This document provides method and materials for treating cancer. In some cases, methods and materials for treating estrogen receptor negative (ER-) cancers (e.g., ER- breast cancers such as triple-negative breast cancers (TNBCs)) are provided. For example, one or more endoxifen (ENDX) compounds can be administered to a mammal (e.g., a human) having an ER- cancer (e.g., an ER- breast cancer such as a TNBC) to treat that mammal. For example, one or more ENDX compounds and one or more agents / therapies that can alter the antigens presented on the surface of a cancer cell can be administered to a mammal (e.g., a human) having an ER+ cancer and / or an ER- cancer (e.g., an ER- breast cancer such as a TNBC) to treat that mammal.

Described herein are antibodies and immunoconjugates capable of targeting antigens within the kidney. The antibodies described herein generally a polypeptide, wherein the polypeptide comprises: an antigen-binding domain (e.g., immunoglobulin single-chain domain antibody) and a Fc domain, wherein the antigen-binding domain binds an antigen present within the kidney.

Aspects of this invention relate to a novel monoclonal antibody specifically designed to exhibit selective binding affinity towards antigens present predominantly in X chromosome sperm. The antibody is engineered for applications to sex select sperm for cattle breeding purposes.

The invention discloses a TCR (T cell receptor) for recognizing an HPV16 (human papilloma virus 16) antigen and application of the TCR, and provides a T cell receptor for recognizing an HPV16 E7 antigen presented on HLA-A02: 01, and the T cell receptor is named as nwTCR-0541. The HDR vector constructed by the TCR sequence is used for electrotransfection of primary T cells (sorted CD4 + cells and CD8 + cells), has very high gene knock-in efficiency, has very high affinity when being combined with an LLMGTLGIVC-HLA-A * 02: 01 compound, and has a very strong in-vitro killing effect on CaSki cells.

The present application discloses a kit for combined detection of multiple virus antigens and an application method thereof. The application method includes: placing the collected sample in an extraction tube; squeezing the bottle body of the extraction tube multiple times and standing for a preset time period to obtain a sample solution; wherein, the extraction tube contains a sample extraction solution that can simultaneously process multiple antigens; dropping the sample solution on multiple preset test strips and waiting for the antigens in the sample solution to react with the antibodies on the test strips; after the antigens in the sample solution react with the antibodies on the test strips, obtaining a test result based on the quality control line and the detection line set on the test strips. In the present application, dropping the same sample solution on different test strips can quickly determine the antigens present in the sample, and different test strips do not affect each other in terms of reaction and color development, improving the accuracy. Therefore, the detection efficiency of the virus is improved.

The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.

This invention relates to a T-cell receptor capable of binding to the HPV16 E6 antigen presented by the HLA-C*14:02 molecule. The T-cell receptor comprises: αCDR1 (amino acid sequence as shown in SEQ ID NO:1), αCDR2 (amino acid sequence as shown in SEQ ID NO:3), αCDR3 (amino acid sequence as shown in SEQ ID NO:5), βCDR1 (amino acid sequence as shown in SEQ ID NO:11), βCDR2 (amino acid sequence as shown in SEQ ID NO:13), and βCDR3 (amino acid sequence as shown in SEQ ID NO:15). This invention provides a novel and precise immunotherapy strategy for patients with HLA-C*14:02 genotype HPV-related cervical cancer, significantly expanding the applicable population for TCR-T therapy.